Mobile Coping Skills Training to Improve Cardiorespiratory Failure Survivors' Psychological Distress (Blueprint)

June 2, 2022 updated by: Duke University

Optimizing a Self-directed Mobile Coping Skills Training Intervention to Improve Cardiorespiratory Failure Survivors' Psychological Distress

This is a pilot randomized clinical trial involving adult survivors of cardiorespiratory failure treated in intensive care units (ICUs) that is designed to test the acceptability, feasibility, and clinical impact of a coping skills training intervention (Blueprint) delivered via a mobile app. This trial will allow us to determine if new changes to intervention delivery, inclusion criteria, and other factors are successful. It will also inform the development of a next-step efficacy focused trial.

Study Overview

Detailed Description

As survival has improved for the 2 million people with cardiorespiratory failure managed annually in US intensive care units (ICUs), research has clarified how these survivors suffer from severe and persistent symptoms of psychological distress-depression, anxiety, and post-traumatic stress disorder (PTSD)-after discharge. However, few interventions exist that are relevant to patients' experiences and that also accommodate their many physical, social, and financial barriers to personalized care. To fill this gap, we developed a telephone- and web-based coping skills training (CST) program.

CST is an empirically-supported psychosocial intervention that targets the use of the adaptive coping skills to decrease psychological distress and improve quality of life. We conducted a multicenter randomized clinical trial (RCT) called CSTEP that compared CST to an education program (EP) among a general sample of ICU survivors who received mechanical ventilation for cardiorespiratory failure. CST reduced depression symptoms and improved quality of life at 6 months in a pre-specified subgroup with elevated baseline distress. This RCT also identified key questions regarding best practices for identi-fying patients who are highly distressed yet whose physical illness is manageable, as well as delivering the intervention in a more convenient, and scalable manner. In a recent RCT testing a mindfulness intervention (LIFT), we found that a self-directed mobile app approach increased dose, adherence, and retention. However, many patients reported low enthusiasm for a meditation-based intervention.

What is needed before a second multicenter RCT is to apply the promising CST content to a LIFT-inspired mobile app-based delivery system, and then to test it within a targeted patient population with a high likelihood of response (i.e., high baseline psychological distress). Therefore, we propose a 2-year R34 mixed-methods project that includes a pilot RCT in which we will randomize 45 cardiorespiratory failure / insufficiency survivors to one of three arms in equal ratios: intervention plus therapist for non-responders (n ~15), intervention without a therapist (n ~15), and usual care control (n ~15). Randomization will be stratified by ICU service (medical vs. surgical), baseline HADS score (<14 vs. ≥14), and age (<50 vs. ≥50). Our specific aims will: (1) Optimize the usability of a self-directed mobile app (Blueprint) and an automated post-discharge distress screening system; (2) Test two promising iterations of Blueprint vs. usual care in a pilot 3-arm RCT with 3-month follow up, and (3) Explore facilitators and barriers to Blueprint implementation, using these data to inform any necessary final revisions to the Blueprint app.

Study Type

Interventional

Enrollment (Actual)

45

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • North Carolina
      • Durham, North Carolina, United States, 27710
        • Duke University Medical Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

14 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

INCLUSION CRITERIA

  1. Adult (age ≥18)
  2. Managed in a hospital setting for ≥24 hours during the time inclusion criterion #3 is met.
  3. Acute cardiorespiratory failure / insufficiency, defined as ≥1 of the following:

    • mechanical ventilation via endotracheal tube for ≥4 hours
    • non-invasive ventilation (CPAP, BiPAP) for ≥4 hours in a 24-hour period provided for acute respiratory failure
    • new use of supplemental oxygen ≥2 liters per minute (or increase in baseline continuous oxygen)
    • use of vasopressors for shock of any etiology
    • use of inotropes for shock of any etiology
    • use of pulmonary vasodilators
    • use of aortic balloon pump or cardiac assist device for cardiogenic shock
    • use of diuretic intravenous drip
  4. Cognitive status intact

    • No history of pre-existing significant cognitive impairment (e.g., dementia) as per medical chart
    • Absence of current significant cognitive impairment (impairment defined as ≥3 errors on the Callahan cognitive status screen)
    • Decisional capacity present
  5. Absence of severe and/or persistent mental illness

    • Treatment for severe and/or persistent mental illness (e.g., psychosis, bipolar affective disorder, schizoaffective disorder, schizoid personality disorder, schizophrenia [as per medical record], hospitalization for any psychiatric disorder) within the 6 months preceding the current hospital admission
    • No endorsement of active suicidality at time of admission or informed consent
    • No active substance abuse at a severity that impairs ability to participate
  6. Functional English fluency

EXCLUSION CRITERIA (in hospital):

  1. Complex medical care expected soon after discharge (e.g., planned surgeries, transplantation evaluation, extensive travel needs for follow up care, disruptive chemotherapy/radiation regimen)
  2. Unable to complete study procedures as determined by staff
  3. Lack of access to either reliable smartphone with cellular data plan or wifi

INCLUSION CRITERIA (post-discharge)

1. Elevated baseline (T1) psychological distress symptoms, defined as HADS total score of ≥8

EXCLUSION CRITERIA (post-discharge)

  1. Failure to randomize within 2 months post-discharge.
  2. Failure to access app within 1 month after randomization in the absence of other explanation (e.g., hospitalization).

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: coping skills training plus therapist input
Participants will receive a CST therapist call within 48 hours of randomization to discuss the study rationale, to conduct a relaxation exercise, and to review app and study logistics. Participants will use the Blueprint mobile app for 1 month.
The intervention is a mobile app that delivers a 4-week long program of coping skills training. The app contains video, visual, and text content and has a companion PDF workbook. It provides timeline-driven prompts to complete weekly tasks (e.g., viewing videos, completing surveys) and coaching participants to use their current stressors as context for real-life application of adaptive coping skills. A therapist will call participant to introduce the intervention and perform a brief relaxation exercise.
Other Names:
  • Blueprint; mobile coping skills training (mCST) plus therapist
Experimental: coping skills training without therapist input
Participants will receive a call from a research coordinator to get them started with the trial. Participants will use the Blueprint mobile app for 1 month. No therapist calls will be provided. Chat room access in the app will be provided.
The intervention is a mobile app that delivers a 4-week long program of coping skills training. The app contains video, visual, and text content and has a companion PDF workbook. It provides timeline-driven prompts to complete weekly tasks (e.g., viewing videos, completing surveys) and coaching participants to use their current stressors as context for real-life application of adaptive coping skills. App chat room access will be provided.
Other Names:
  • Blueprint; mobile coping skills training (mCST)
No Intervention: usual care control
Control participants will receive the same safety oversight as intervention participants and will be provided with phone and email contacts for study staff.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Hospital Anxiety and Depression Scale (HADS) questionnaire
Time Frame: Between baseline and 1 month post-randomization
Depression and anxiety symptoms. Scores range from 0 (better) to 42 (worse)
Between baseline and 1 month post-randomization

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Hospital Anxiety and Depression Scale (HADS) questionnaire
Time Frame: Between baseline and 3 months post-randomization
Depression and anxiety symptoms. Scores range from 0 (better) to 42 (worse)
Between baseline and 3 months post-randomization
Change in Post-Traumatic Stress Symptom inventory (PTSS)
Time Frame: Between baseline and 1 month post-randomization
Post-traumatic stress disorder symptoms. Scores can range from 10 (best) to 70 (worst).
Between baseline and 1 month post-randomization
Change in Post-Traumatic Stress Symptom inventory (PTSS)
Time Frame: Between baseline and 3 months post-randomization
Post-traumatic stress disorder symptoms. Scores can range from 10 (best) to 70 (worst).
Between baseline and 3 months post-randomization
Client Satisfaction Questionnaire (CSQ)
Time Frame: 1 month post-randomization
A measure of acceptability. Scores can range from 8 (worst) to 32 (best)
1 month post-randomization
Systems Usability Scale (SUS)
Time Frame: 1 month post-randomization

A measure of intervention usability. Each of 10 items is scored from 1 to 5. For each of the odd numbered questions, subtract 1 from the score.

For each of the even numbered questions, subtract their value from 5. Take these new values and add up the total score. Then multiply this by 2.5.Scores can range from 0 (worst) to 100 (best)

1 month post-randomization
Intervention adherence
Time Frame: 1 month post-randomization
Quantified by number of intervention sessions, weekly surveys, and intervention
1 month post-randomization
Change in quality of life visual analog scale
Time Frame: Between baseline and 1 month post-randomization
A measure of quality of life. Scores can range from 0 (worst) to 100 (best)
Between baseline and 1 month post-randomization
Change in quality of life visual analog scale
Time Frame: Between baseline and 3 month post-randomization
A measure of quality of life. Scores can range from 0 (worst) to 100 (best)
Between baseline and 3 month post-randomization
Change in Patient Health Questionnaire 10-item scale (PHQ-10)
Time Frame: Between baseline and 1 month post-randomization
An adapted version of the PHQ-15; a measure of physical symptoms. Scores can range from 10 (best) to 20 (worst).
Between baseline and 1 month post-randomization
Change in Patient Health Questionnaire 10-item scale (PHQ-10)
Time Frame: Between baseline and 3 months post-randomization
An adapted version of the PHQ-15; a measure of physical symptoms. Scores can range from 10 (best) to 20 (worst).
Between baseline and 3 months post-randomization
Distress associated with depression and anxiety symptom frequency
Time Frame: Between baseline and 1 month post-randomization
A visual analog scale appended to the HADS which allows participants to report how distressing they perceive the depression and anxiety symptoms to be that they reported in the HADS. Scores range from 0 (best) to 100 (worst)
Between baseline and 1 month post-randomization
Distress associated with depression and anxiety symptom frequency
Time Frame: Between baseline and 3 months post-randomization
A visual analog scale appended to the HADS which allows participants to report how distressing they perceive the depression and anxiety symptoms to be that they reported in the HADS. Scores range from 0 (best) to 100 (worst)
Between baseline and 3 months post-randomization
Distress associated with PTSD symptom frequency
Time Frame: Between baseline and 1 month post-randomization
A visual analog scale appended to the PTSS which allows participants to report how distressing they perceive the depression and anxiety symptoms to be that they reported in the PTSS. Scores range from 0 (best) to 100 (worst)
Between baseline and 1 month post-randomization
Distress associated with PTSD symptom frequency
Time Frame: Between baseline and 3 months post-randomization
A visual analog scale appended to the PTSS which allows participants to report how distressing they perceive the depression and anxiety symptoms to be that they reported in the PTSS. Scores range from 0 (best) to 100 (worst)
Between baseline and 3 months post-randomization

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: Christopher E Cox, MD, Duke University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 3, 2020

Primary Completion (Actual)

December 31, 2021

Study Completion (Actual)

March 31, 2022

Study Registration Dates

First Submitted

March 30, 2020

First Submitted That Met QC Criteria

March 30, 2020

First Posted (Actual)

April 1, 2020

Study Record Updates

Last Update Posted (Actual)

June 3, 2022

Last Update Submitted That Met QC Criteria

June 2, 2022

Last Verified

January 1, 2022

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

Yes

IPD Plan Description

We will follow all NIH guidelines and regulations.

IPD Sharing Time Frame

We will follow NIH and institutional guidelines.

IPD Sharing Access Criteria

We will follow NIH and institutional guidelines.

IPD Sharing Supporting Information Type

  • Study Protocol
  • Statistical Analysis Plan (SAP)
  • Informed Consent Form (ICF)
  • Clinical Study Report (CSR)
  • Analytic Code

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cardiorespiratory Failure

Subscribe